奥浦迈：公司生产经营一切正常

Core Viewpoint - The company emphasizes that its stock price fluctuations in the secondary market are influenced by various factors, including international conditions, macroeconomic environment, market trends, sector rotation, market sentiment, and funding status [1] Group 1: Company Operations - The company reports that its production and operations are normal, with steady business progress and no significant hidden dangers or operational risks [1] - The company completed the asset transfer for a major asset restructuring on January 15, 2026, with Pengli Bio included in the consolidated financial statements starting from that date [1] Group 2: Financial Performance - The company disclosed its 2025 annual performance forecast on January 31, 2026, with specific details available in the announcement [1] Group 3: Investor Relations - The company maintains open communication with investors during non-sensitive periods and keeps its investor relations contact information accessible [1] - The company has consistently rewarded investors through annual and interim dividends, share buybacks, and voluntary performance announcements over the past few years [1] Group 4: Future Strategy - The company will continue to focus on its core business, prioritize product innovation, and enhance its intrinsic investment value to improve operational quality and strengthen core competitiveness [1] - The company is committed to the development philosophy of "investor-centric" and aims to create long-term investment value for shareholders through better performance [1]